- Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basis
- Third quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%
- For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidance
WARSAW, Ind., Nov. 5, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025. The Company reported third quarter net sales of $2.001 billion, an increase of 9.7% over the prior year period, an increase of 8.6% on a constant currency1 basis and an increase of 5.0% on an organic constant currency1 basis. Net earnings for the third quarter were $230.9 million, or $377.0 million on an adjusted1 basis.
Diluted earnings per share were $1.16 for the third quarter, and adjusted1 diluted earnings per share were $1.90, an increase of 9.2%.
| 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. |
“Our third quarter performance was anchored by 5.6% organic revenue growth in our critical U.S. business, driven by accelerated adoption of our key new products referred to as the ‘Magnificent Seven,'” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “This is highly encouraging, especially as we prepare to launch a second round of new-to-the-world technologies, including the first fully autonomous robot in orthopedics and our iodine treated hip, the world’s first orthopedic implant with Iodine Technology that inhibits bacterial adhesion and prevents biofilm formation to help address Periprosthetic Joint Infections. We are excited to launch our iodine treated hip in Japan soon, having received PMDA approval in September. All that said, our strong performance in the U.S. was partially offset by weakness in Latin America, Emerging Markets in Europe and non-core businesses, which emerged late in the quarter and are being addressed.”
Recent Highlights
- Completed the acquisition of Monogram Technologies , adding surgeon-guided semi- and fully autonomous robotic technology that will create the industry’s broadest, most flexible portfolio of orthopedic robotics and navigation solutions.
- Announced Japan PMDA approval of iTaperloc® Complete and iG7 Hip System, the world’s first orthopedic implants with iodine technology.
- Launched two new foot and ankle solutions for complex trauma cases , continuing the track record of innovation from the Company’s Paragon 28 business.
- Recognized by Fortune as one of the best 100 companies to work for in Europe.
- Showcased latest innovations at the American Association of Hip and Knee Surgeons Annual Meeting and the American Orthopedic Foot and Ankle Society Annual Conference.
Geographic and Product Category Sales
The following sales tables provide results by geography and product category for the three and nine-month periods ended September 30, 2025, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis. Percentage change is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28, Inc. (“Paragon 28”).
